DouillardJ-Y, SobreroA., Van CutsemE.Standard of care in metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.Ann Oncol,14(suppl. 2): ii7–ii12, 2003.
2.
SaltzL.B., CoxJ.V., BlankeC.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: irinotecan study group.N Engl J Med,343: 905–914, 2000.
3.
DouillardJ-V, CunninghamD., RothA.D.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial.Lancet,355: 1041–1047, 2000.
4.
AdamR.Chemotherapy and surgery: new perspectives on the treatment of unresectable metastases.Ann Oncol,14(suppl. 2): ii13–ii16, 2000.
5.
PozzoC., BassoM., CassanoA.Neoadjuvant treatment of metastatic liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.Proc Eur Soc Med Oncol,13(suppl. 5): abstr 293P, 2002.
6.
KöeneC-H, Van CutsemE., WilsJ-AIrinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986.Proc ASCO,22: abstr 1018, 2003.
7.
CunninghamD., HumbletY., SienaS.Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC).Proc ASCO,22: abstr 1012, 2003.
8.
HurwitzH., FehrenbacherL., CartwrightT.Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC). Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC.Proc ASCO,22: abstr 3646, 2003.
MeyerA., TakimotoM., FritzE.The prognostic significance of proliferative cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer.Cancer,71: 2454–2460, 1993.
11.
PrewettM., HooperA., BassiR.Growth of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody in combination with 5-fluorouracil or irinotecan.Proc Am Ass Cancer Res,4447: 287 (Abstr 1543), 2001.
12.
SaltzL.B., RubinM., HochsterH.Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR).Proc ASCO,20: abstr 7, 2001.
13.
SchoffskiP., LutzM-P, FolprechtG.Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metastatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR).Proc ASCO,21: abstr 7, 2002.
14.
Van LaethemJ-L, RaoulJ-L, MitryE.Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results.Proc ASCO,22: abstr 1058, 2003.
15.
FernandoN-H, HurwitzH-I.Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.Semin Oncol,30(3 Suppl 6): 39–50, 2003.
16.
ChoiH., HyunM.S., JungG.J.Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence.Oncology,55: 575–581, 1998.
17.
CassanoA., BagalaC., BattelliC.Expression of vascular endothelial growth factor, mitogenactivated protein kinase and p53 in human colorectal cancer.Anticancer Res,22: 2179–2184, 2002.
18.
LandriscinaM., CassanoA., RattoC.Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.Br J Cancer,78: 765–770, 1998.
19.
FolkmanJ.What is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst,82: 4–6, 1990.
20.
KabbinavarF., HurwitzH-I, FehrenbacherL.Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol,21: 60–65, 2003.
